Harmony Biosciences Holdings (HRMY) Stock Analysis

Harmony Biosciences Holdings (HRMY) is a publicly traded company in the HEALTHCARE sector. It trades at $30.91, carries a market capitalization of $1.84B, a price-to-earnings ratio of 12.83. This page summarizes the public market data, fundamentals, and frequently asked questions for HRMY, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Harmony Biosciences Holdings currently has a Neutral sentiment score of 0.07.

About Harmony Biosciences Holdings

Harmony Biosciences Holdings, Inc. is a prominent commercial-stage pharmaceutical company headquartered in Plymouth Meeting, Pennsylvania, focusing on the development and commercialization of innovative therapies for rare neurological disorders. The company’s flagship products target conditions such as narcolepsy, reflecting its commitment to addressing significant unmet medical needs in the neurology field. With a robust pipeline supported by advanced research capabilities, Harmony is dedica...

GNG Research Analysis

GNG Research scores Harmony Biosciences Holdings (HRMY) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for HRMY.

Frequently Asked Questions

Does HRMY pay dividends?

Harmony Biosciences Holdings (HRMY) does not currently pay a regular dividend.

What is HRMY's P/E ratio?

Harmony Biosciences Holdings has a price-to-earnings (P/E) ratio of 12.83.

What is HRMY's market cap?

Harmony Biosciences Holdings (HRMY) has a market capitalization of $1.84B with a current stock price of $30.91.